Alzheon Inc is a clinical-stage biotechnology company focused on brain health, memory and aging. The company develops innovative treatments for Alzheimer's disease and other neurodegenerative disorders.In April 2022, Alzheon Inc completed an oversubscribed $50 million Series D.In April 2018, the company offered 5,000,000 shares of its common stock at an initial public offering price between $13.00 and $15.00 per share. At that time, the company expected to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price. The shares were expected to trade on The Nasdaq Global Market under the ticker symbol "ALZH". Later that month, the company postponed its $70 million fund raised by the offering and the company expected to have commanded a fully diluted market value of $228 million, at the mid-point.In March 2018, the company raised approximately $81 million in an initial public offering.In Ap